Tracking side effects of T-DXd for advanced breast cancer
Part of Cancer, Skin clinical trials.
This study looks at people with advanced breast cancer who will receive a drug called T-DXd. Researchers want to understand the side effects of this treatment by analyzing blood samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with advanced breast cancer that has spread beyond the breast.
- Your cancer must be either HER2-positive or HER2-low/ultralow (levels of a protein on cancer cells).
- Your doctor has decided to treat you with T-DXd as part of your normal care.
- You agree to give extra blood samples for research purposes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
This trial tests a combination of two drugs, T-DXd (a targeted therapy) and an immunotherapy, before surgery for people with early-stage breast cancer that has low levels of HER2 and is hormone receptor positive. The goal is to see if this treatment can shrink the tumor or eliminate cancer cells before surgery.
This trial is studying a drug called T-DXd (trastuzumab deruxtecan) for Chinese women with advanced breast cancer that has a certain protein (HER2) either in high or low amounts. It aims to see how well the drug works in real-world settings.
This trial studies how the drug T-DXd (trastuzumab-deruxtecan) works in people with advanced or metastatic breast cancer. It compares drug levels in the body based on body mass index (BMI) to see if dose adjustments are needed.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.